Epigenetic regulation of maspin expression in human ovarian carcinoma cells

Gynecologic Oncology

Volumn 102, Issue 2, 2006, Pages 319-324

  Rose, Stephen L ^a   Fitzgerald, Matthew P ^a   White, Natalie O ^a   Hitchler, Michael J ^a   Futscher, Bernard W ^b   De Geest, Koen ^a   Domann, Frederick E ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Cancer; Chromatin; Methylation; Serpin

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BISULFITE; CYTOSINE; MASPIN; PROTEIN P53;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CHROMATIN; CHROMATIN STRUCTURE; CONTROLLED STUDY; DEMETHYLATION; EPIGENETICS; EPITHELIUM CELL; FEMALE; GENE CONTROL; GENE SEQUENCE; HUMAN; HUMAN CELL; METHYLATION; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WILD TYPE;

CHROMATIN; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; OVARIAN NEOPLASMS; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; SERPINS;

EID: 33745964874     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.12.025     Document Type: Article

References (28)

1. American Cancer Society. Cancer Facts and Figures 2005 (2005), American Cancer Society, Atlanta
2. Sager R., Sheng S., Pemberton P., and Hendrix M.J. Maspin: a tumor suppressing serpin. Curr. Top. Microbiol. Immunol. 213 (1996) 51-64
3. Seftor R.E., Seftor E.A., Sheng S., Pemberton P.A., Sager R., and Hendrix M.J. Maspin suppresses the invasive phenotype of human breast carcinoma. Cancer Res. 58 (1998) 5681-5685
4. Sheng S., Carey J., Seftor E.A., Dias L., Hendrix M.J., and Sager R. Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 11669-11674
5. Zou Z., Anisowicz A., Hendrix M.J., Thor A., Neveu M., Sheng S., et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 263 (1994) 526-529
6. Zhang M., Volpert O., Shi Y.H., and Bouck N. Maspin is an angiogenesis inhibitor. Nat. Med. 6 (2000) 196-199
7. Zou Z., Gao C., Nagaich A.K., Connell T., Saito S., Moul J.W., et al. p53 regulates the expression of the tumor suppressor gene maspin. J. Biol. Chem. 275 (2000) 6051-6054
8. Boltze C., Schneider-Stock R., Quednow C., Hinze R., Mawrin C., Hribaschek A., et al. Silencing of the maspin gene by promoter hypermethylation in thyroid cancer. Int. J. Mol. Med. 12 (2003) 479-484
9. Mueller E., Sarraf P., Tontonoz P., Evans R.M., Martin K.J., and Zhang M. Terminal differentiation of human breast cancer through PPAR gamma. Mol. Cell 1 (1998) 465-470
10. Jiang W.G., Hiscox S., Horrobin D.F., Bryce R.P., and Mansel R.E. Gamma linolenic acid regulates expression of maspin and the motility of cancer cells. Biochem. Biophys. Res. Commun. 237 (1997) 639-644
11. Maass N., Hojo T., Ueding M., Luttges J., Kloppel G., Jonat W., et al. Expression of the tumor suppressor gene maspin in human pancreatic cancers. Clin. Cancer Res. 7 (2001) 812-817
12. Yatabe Y., Mitsudomi T., and Takahashi T. Maspin expression in normal lung and non-small-cell lung cancers: cellular property-associated expression under the control of promoter DNA methylation. Oncogene 23 (2003) 4041-4049
13. Akiyama Y., Maesawa C., Ogasawara S., Terashima M., and Masuda T. Cell-type-specific repression of the maspin gene is disrupted frequently by demethylation at the promoter region in gastric intestinal metaplasia and cancer cells. Am. J. Pathol. 163 (2003) 1911-1919
14. Sood A.K., Fletcher M.S., Gruman L.M., Coffin J.E., Jabbari S., Khalkhali-Ellis Z., et al. The paradoxical expression of maspin in ovarian carcinoma. Clin. Cancer Res. 8 (2002) 2924-2932
15. Futscher B.W., Oshiro M.M., Wozniak R.J., Holtan N., Hanigan C.L., Duan H., et al. Role for DNA methylation in the control of cell type-specific maspin expression. Nat. Genet. 31 (2002) 175-179
16. Domann F.E., Rice J.C., Hendrix M.J., and Futscher B.W. Epigenetic silencing of maspin gene expression in human breast cancers. Int. J. Cancer 85 (2000) 805-810
17. Futscher B.W., O'Meara M.M., Kim C.J., Rennels M.A., Lu D., Gruman L.M., et al. Aberrant methylation of the maspin promoter is an early event in human breast cancer. Neoplasia 6 (2004) 380-389
18. Fitzgerald M., Oshiro M., Holtan N., Krager K., Cullen J.J., Futscher B.W., et al. Human pancreatic carcinoma cells activate maspin expression through loss of epigenetic control. Neoplasia 5 (2003) 427-436
19. Roland I.H., Yang W.L., Yang D.H., Daly M.B., Ozols R.F., Hamilton T.C., et al. Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomies. Cancer 98 (2003) 2607-2623
20. Capo-chichi C.D., Smith E.R., and Yang D.H. Dynamic alterations of the extracellular environment of ovarian surface epithelial cells in premalignant transformation, tumorigenicity, and metastasis. Cancer 95 (2002) 1802-1815
21. Dyck H.G., Hamilton T.C., Godwin A.K., Lynch H.T., Maines-Bandiera S., and Auersperg N. Autonomy of the epithelial phenotype in human ovarian surface epithelium: changes with neoplastic progression and with a family history of ovarian cancer. Int. J. Cancer 69 (1996) 429-436
22. He T.C., Zhou S., da Costa L.T., Yu J., Kinzler K.W., and Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. 95 (1998) 2509-2514
23. Clark S.J., Harrison J., Paul C.L., and Frommer M. High sensitivity mapping of methylated cytosines. Nucleic Acids 22 (1994) 2990-2997
24. Rao S., Procko E., and Shannon M.F. Chromatin remodeling, measured by a novel real-time polymerase chain reaction assay, across the proximal promoter region of the IL-2 gene. J. Immunol. 167 (2001) 4494-4503
25. Olivier M., Eeles R., Hollstein M., Khan M.A., Harris C.C., and Hainaut P. The IARC TP53 Database: new online mutation analysis and recommendations to users. Hum. Mutat. 19 6 (2002) 607-614
26. Skilling J.S., Squatrito R.C., Connor J.P., Niemann T., and Buller R.E. p53 gene mutation analysis and antisense-mediated growth inhibition of human ovarian carcinoma cell lines. Gynecol. Oncol. 60 (1996) 72-80
27. Oshiro M.M., Watts G.S., Wozniak R.J., Junk D.J., Munoz-Rodriguez J.L., Domann F.E., et al. Mutant p53 and aberrant cytosine methylation cooperate to silence gene expression. Oncogene 22 (2003) 3624-3634
28. Jones P.L., Veenstra G.J., Wade P.A., Vermaak D., Kass S.U., Landsberger N., et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat. Genet. 19 (1998) 187-191